I can see a potential where the product produced is in a lag situation for the June Qtr, and was in an advanced situation for the March Qtr.
as we know, the March Qtr production benefited from a larger than usual HMC stockpile coming from the December Qtr.Due to the downtime of the DMU in the March Qtr it's likely that KMS used up most of the HMC produced in the March Qtr and ended with low HMC stockpiles. This would mean that the June Qtr production didn't benefit from a HMC stockpile from March but conversely would have ended up with a HMC stockpile at the end of June which wasn't shown as final product.
i imagine that this scenario would play havoc with trying to work out grade like you've been attempting?
So on the basis foreshadowed above a steady state production level for Sep and Dec qtrs that generates revenue of circa $70mil under current OS, cost and pricing conditions looks pretty realistic to me.
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 5B Cash Flow Report
SFX
sheffield resources limited
Add to My Watchlist
8.57%
!
19.0¢

I can see a potential where the product produced is in a lag...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
19.0¢ |
Change
0.015(8.57%) |
Mkt cap ! $75.01M |
Open | High | Low | Value | Volume |
19.5¢ | 19.5¢ | 18.0¢ | $22.45K | 119.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 69125 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 13115 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 69125 | 0.180 |
1 | 850 | 0.175 |
1 | 265138 | 0.170 |
2 | 293340 | 0.160 |
1 | 35000 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 42155 | 2 |
0.225 | 13000 | 1 |
0.230 | 196888 | 1 |
0.240 | 20000 | 1 |
0.000 | 0 | 0 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
SFX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online